Purple Biotech (PPBT) Change in Accured Expenses (2018 - 2026)

Purple Biotech (PPBT) has 9 years of Change in Accured Expenses data on file, last reported at $296000.0 in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 127.69% year-over-year to $296000.0 in Q1 2026; TTM through Mar 2026 was $371000.0, a 123.92% increase from a year earlier, with the FY2025 full-year figure at $205000.0, up 108.72% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $296000.0, down from $305000.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for PPBT reached as high as $2.7 million in Q1 2022 and fell as low as -$1.5 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged -$46764.7 across 5 years, with a median of -$2000.0 in 2025.
• Across the five-year window, Change in Accured Expenses slumped 2106.06% in 2024 and surged 145.25% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $1.6 million in 2022, then tumbled by 89.07% to $179000.0 in 2023, then slumped by 476.54% to -$674000.0 in 2024, then jumped by 145.25% to $305000.0 in 2025, then fell by 2.95% to $296000.0 in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $296000.0 in Q1 2026, $305000.0 in Q4 2025, and -$2000.0 in Q3 2025.